Medexus Pharmaceuticals Inc MEDXF

MEDXF gets CRL

[Finallytherock]

Needs more trials. Company is falling apart. Ceo had indicated approval was in the bag. Decreasing revenues from products, shake up in management, no nasdaq listing. Awful,

[GoldenArm]

None of what you said is true. This is the FDA playing games. Revenues increasing and not listing on the Nasdaq was a good thing because of the games the US market plays. This is a temporary blow. A good time to add. I'm not happy with the news but MDP is a solid company run by solid management.

[Finallytherock]

None of what you said is true. The ceo had mentioned many times he felt extremely confident approval would happen and that they would get expanded indication for pediatric. This was somewhat based on their discussions with the fda. Go back and listen to the calls. They missed their numbers last quarter and if you look at the comparison to last quarter, they decreased which was a big question for

[snootchybootchy]

Your posts do not make much sense. The uncertainty in Treo's approval from the FDA was already priced in. You think it would have been trading at around 1.5x TTM revs if investors thought Treo's approval was a sure thing?

[GoldenArm]

Very true. If Treo was a sure thing the stock would have been much higher price. FDA games are a common thing and Yes the company needs to work with them quickly to get things back on track. Management was confident but you never know who was pulling strings in the background to de-rail (temporarily) plans. FDA is a joke and this pandemic proved it.

[Finallytherock]

Disagree. This is a canadian company so very few, especially US investors, really follow the story. The volume is next to nothing. The valuation is normally discounted to what a US company would trade at plus biotech is completely out of favor so even US companies who are actually getting FDA approval go down. My concern was that getting fda approval may not move this stock that much. Now, with a

[GoldenArm]

If you had 100% safe cure for cancer FDA would reject it because they look at how it would effect big pharma. Why the road block to list on Nasdaq? Who was pulling strings in the background to keep MDP off the Nasdaq? Here is what Ken said " "In the fourth quarter of fiscal 2021, IXINITY sales declined as pharmacy and wholesale customers worked through inventory on hand. In addition,